Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jai Radhakrishnan

Showing results (41-50 of 225) with videos related to

Pageof 23
Sort By:
Kidney International Reports|January 1, 2019
<i>KI Reports</i> in 2019: Further Expanding Access to Research in NephrologyJai Radhakrishnan, Sumit Mohan, Radha McLean
Frontiers in Pediatrics|October 7, 2015
The Evidence-Based Approach to Adult-Onset Idiopathic Nephrotic SyndromePietro A A Canetta, Jai Radhakrishnan
Kidney International Reports|January 11, 2018
<i>Kidney International Reports</i>: The First YearSumit Mohan, Radha McLean, Jai Radhakrishnan
Kidney International Reports|January 10, 2022
Six Years of <i>KI Reports</i>: Milestones Behind and AheadRadha McLean, Sumit Mohan, Jai Radhakrishnan
Kidney International Reports|February 12, 2020
<i>Kidney International Reports</i>: Three Years of PublicationSumit Mohan, Radha McLean, Jai Radhakrishnan
Kidney International|March 21, 2017
Capillary leak syndrome: etiologies, pathophysiology, and managementEric Siddall, Minesh Khatri, Jai Radhakrishnan
Kidney International Reports|June 2, 2018
<i>Kidney International Reports</i>: Two Years of PublicationSumit Mohan, Radha McLean, Jai Radhakrishnan
Clinical Journal of the American Society of Nephrology : CJASN|May 17, 2014
Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritisJonathan Hogan, Rupali Avasare, Jai Radhakrishnan
Kidney International|June 1, 2012
Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis?Jonathan Hogan, Michael H Schwenk, Jai Radhakrishnan
Kidney International|March 23, 2019
Intensive BP control and incident kidney disease: what can we learn from urinary biomarkers?T Alp Ikizler, Jai Radhakrishnan, Germaine Wong
Pageof 23

Showing results (41-50 of 225) with videos related to

Sort By:
Pageof 23
Kidney International Reports|January 1, 2019
<i>KI Reports</i> in 2019: Further Expanding Access to Research in NephrologyJai Radhakrishnan, Sumit Mohan, Radha McLean
Frontiers in Pediatrics|October 7, 2015
The Evidence-Based Approach to Adult-Onset Idiopathic Nephrotic SyndromePietro A A Canetta, Jai Radhakrishnan
Kidney International Reports|January 11, 2018
<i>Kidney International Reports</i>: The First YearSumit Mohan, Radha McLean, Jai Radhakrishnan
Kidney International Reports|January 10, 2022
Six Years of <i>KI Reports</i>: Milestones Behind and AheadRadha McLean, Sumit Mohan, Jai Radhakrishnan
Kidney International Reports|February 12, 2020
<i>Kidney International Reports</i>: Three Years of PublicationSumit Mohan, Radha McLean, Jai Radhakrishnan
Kidney International|March 21, 2017
Capillary leak syndrome: etiologies, pathophysiology, and managementEric Siddall, Minesh Khatri, Jai Radhakrishnan
Kidney International Reports|June 2, 2018
<i>Kidney International Reports</i>: Two Years of PublicationSumit Mohan, Radha McLean, Jai Radhakrishnan
Clinical Journal of the American Society of Nephrology : CJASN|May 17, 2014
Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritisJonathan Hogan, Rupali Avasare, Jai Radhakrishnan
Kidney International|June 1, 2012
Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis?Jonathan Hogan, Michael H Schwenk, Jai Radhakrishnan
Kidney International|March 23, 2019
Intensive BP control and incident kidney disease: what can we learn from urinary biomarkers?T Alp Ikizler, Jai Radhakrishnan, Germaine Wong
Pageof 23